These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 17942921)

  • 1. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
    Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
    Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
    Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
    Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
    Peyruchaud O; Winding B; Pécheur I; Serre CM; Delmas P; Clézardin P
    J Bone Miner Res; 2001 Nov; 16(11):2027-34. PubMed ID: 11697798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma.
    Littlewood-Evans AJ; Bilbe G; Bowler WB; Farley D; Wlodarski B; Kokubo T; Inaoka T; Sloane J; Evans DB; Gallagher JA
    Cancer Res; 1997 Dec; 57(23):5386-90. PubMed ID: 9393764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
    Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.
    Zhao Y; Bachelier R; Treilleux I; Pujuguet P; Peyruchaud O; Baron R; Clément-Lacroix P; Clézardin P
    Cancer Res; 2007 Jun; 67(12):5821-30. PubMed ID: 17575150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
    Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin K inhibitors as treatment of bone metastasis.
    Le Gall C; Bonnelye E; Clézardin P
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):218-22. PubMed ID: 18685424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer.
    Parker BS; Ciocca DR; Bidwell BN; Gago FE; Fanelli MA; George J; Slavin JL; Möller A; Steel R; Pouliot N; Eckhardt B; Henderson MA; Anderson RL
    J Pathol; 2008 Feb; 214(3):337-46. PubMed ID: 17985332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histochemical evidence of osteoclastic degradation of extracellular matrix in osteolytic metastasis originating from human lung small carcinoma (SBC-5) cells.
    Li M; Amizuka N; Takeuchi K; Freitas PH; Kawano Y; Hoshino M; Oda K; Nozawa-Inoue K; Maeda T
    Microsc Res Tech; 2006 Feb; 69(2):73-83. PubMed ID: 16456838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.
    Duivenvoorden WC; Popović SV; Lhoták S; Seidlitz E; Hirte HW; Tozer RG; Singh G
    Cancer Res; 2002 Mar; 62(6):1588-91. PubMed ID: 11912125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
    J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
    Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
    Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis.
    Duong LT; Wesolowski GA; Leung P; Oballa R; Pickarski M
    Mol Cancer Ther; 2014 Dec; 13(12):2898-909. PubMed ID: 25249554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
    Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
    J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.